Document is current
Any future updates will be listed below
-
Authors
Bjornstad, Petter https://orcid.org/0000-0002-5160-2947
Chao, Lily C.
Cree-Green, Melanie
Dart, Allison B.
King, Malcolm https://orcid.org/0000-0002-1712-0303
Looker, Helen C.
Magliano, Dianna J. https://orcid.org/0000-0002-9507-6096
Nadeau, Kristen J.
Pinhas-Hamiel, Orit
Shah, Amy S.
van Raalte, Daniel H.
Pavkov, Meda E.
Nelson, Robert G. https://orcid.org/0000-0001-7307-3786
- License Information
-
More Information
Article History
Accepted: 3 October 2022
First Online: 31 October 2022
Competing interests
: P.B. has acted as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chem, Sanofi, Novo Nordisk, Horizon Pharma, XORTX. P.B. serves on the advisory boards of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and XORTX. D.H.v.R. has acted as a consultant and received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck and Sanofi, and received research operating funding from AstraZeneca, Boehringer Ingelheim–Eli Lilly Diabetes Alliance and Merck. The other authors declare no competing interests.
